Alzheimer’s disease has traditionally been viewed as a proteinopathy. However, recent evidence highlights circuit impairments as part of the disease progression. We use mouse models and cell culture systems to dissect the role that neural activity plays in the onset and development of Alzheimer’s disease. We also implement optogenetics to control activity within neuronal circuits and image with multiphoton microscopy to monitor circuit dynamics.

In an attempt to prevent and/or reverse the disorder, we have partnered with industry leaders such as Biogen and NeuroBo Pharmaceuticals to study the effects and mechanisms of action of Alzheimer’s therapeutics such as aducanumab and NB-02. We strongly believe that these translational studies are important for getting effective therapies to patients.